The Future – EVA-PCD® Platform and Targeted Agents

As I mentioned in my last post, in our presentation at the 2010 ASCO Annual Meeting, we showed clinical response rates were doubled by using the Ex-Vivo Analysis of Programmed Cell Death (EVA-PCD®) platform with standard FDA approved chemotherapeutic agents in NSCLC patients.

If we can achieve these types of results by simply reconfiguring existing drugs, it suggests that the EVA-PCD platform could provide even better results as we introduce larger numbers of active, targeted agents.

One such agent, PF-1066 provided an overall response rate of 64 percent when patients were selected for the EML4-ALK fusion oncogene. This type of approach, the selection of candidates for therapy predicated upon the biology of the patient, is precisely the premise underlying all of our work. While the PF-1066 data was strongly positive, it represented a very select population of lung cancer patients who carry a specific gene profile. Of all NSCLC patients, only 3-4 percent carry this gene. While recognizing targets like EGFR and ALK continue to improve responses, the EVA-PCD platform is capable of identifying patients for response even when the specific underlying genetic mechanism may be less well characterized. The capacity of the EVA-PCD platform to measure global cellular response enables us to select candidates for whom no known genetic predisposition exists.